Identification of Potent and Selective Inhibitors of Fat Mass Obesity-Associated Protein Using a Fragment-Merging...

Area of Science:

• Epigenetics
• Medicinal Chemistry
• Molecular Biology

Background:

• Fat mass obesity-associated protein (FTO) is a key DNA/RNA demethylase implicated in obesity, cancer, and neurological disorders.
• FTO's role in epigenetic regulation makes it a significant therapeutic target.
• Existing FTO inhibitors lack selectivity, necessitating the design of novel compounds.

Purpose of the Study:

• To design and synthesize novel FTO-selective inhibitors by merging fragments of known inhibitors.
• To evaluate the selectivity of synthesized compounds against ALKBH5, another demethylase.
• To assess the therapeutic potential of a lead compound in acute monocytic leukemia cells.

Main Methods:

• Fragment-based drug design by merging known FTO inhibitor fragments (Hz and MA).
• Synthesis and structural characterization of novel FTO inhibitor analogues.
• In vitro enzymatic assays to determine FTO and ALKBH5 inhibition selectivity.
• Cell-based assays using acute monocytic leukemia NOMO-1 cells treated with a prodrug of compound 11b.

Main Results:

• Compound 11b, a hybrid of Hz (3) and MA (4) fragments, demonstrated selective inhibition of FTO over ALKBH5.
• Treatment with a prodrug of 11b reduced the viability of NOMO-1 cells.
• The treatment increased levels of the FTO substrate N6-methyladenosine in mRNA.
• Upregulation of MYC and downregulation of RARA were observed, consistent with FTO target gene modulation.

Conclusions:

• Hybrid analogues merging Hz and MA fragments represent a new class of FTO-selective inhibitors.
• Compound 11b shows promise as a therapeutic agent for FTO-related diseases, particularly acute monocytic leukemia.
• The study provides a novel strategy for developing selective epigenetic modulators targeting FTO.